Skip to main content
Top
Published in: Drugs & Aging 11/2006

01-11-2006 | Review Article

Divalproex Sodium for the Treatment of Behavioural Problems Associated With Dementia in the Elderly

Author: Dr Anton P. Porsteinsson

Published in: Drugs & Aging | Issue 11/2006

Login to get access

Abstract

Behavioural and psychological symptoms of dementia (BPSD) are a frequent problem in patients with dementia. The consequences of these neuropsychiatric problems can be significant for both patient and caregiver. Although there is no universally accepted pharmaceutical intervention for the treatment of BPSD, various agents have been studied, including divalproex sodium (valproate semisodium). The results of four placebo-controlled clinical trials are reviewed. None of the studies was sufficient to define clinical practice and the results can be seen as conflicting and inconclusive. Three studies suggested possible short-term efficacy, tolerability and safety of divalproex sodium for agitation and some other neuropsychiatric symptoms associated with dementia in elderly patients; in two of these studies, the findings were obtained only on analysis of secondary outcomes. Benefits of divalproex sodium over placebo were not demonstrated in a fourth study. Further research is needed to determine the optimal use of divalproex sodium for the treatment of neuropsychiatric symptoms of dementia and the long-term benefits, if any, of its use in this patient population.
Literature
1.
go back to reference Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer’ s disease in the US population. Arch Neurol 2003; 60(8): 1119–22PubMedCrossRef Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer’ s disease in the US population. Arch Neurol 2003; 60(8): 1119–22PubMedCrossRef
2.
go back to reference Steele C, Rovner B, Chase GA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. Am J Psychiatry 1990 Aug; 147(8): 1049–51PubMed Steele C, Rovner B, Chase GA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. Am J Psychiatry 1990 Aug; 147(8): 1049–51PubMed
3.
go back to reference Stern Y, Tang MX, Albert MS, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997 Mar 12; 277(10): 806–12PubMedCrossRef Stern Y, Tang MX, Albert MS, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997 Mar 12; 277(10): 806–12PubMedCrossRef
4.
go back to reference Yaffe K, Fox P, Newcomer R, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 2002 Apr 24; 287(16): 2090–7PubMedCrossRef Yaffe K, Fox P, Newcomer R, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 2002 Apr 24; 287(16): 2090–7PubMedCrossRef
5.
go back to reference Wancata J, Windhaber J, Krautgartner M, et al. The consequences of non-cognitive symptoms of dementia in medical hospital departments. Int J Psychiatry Med 2003; 33(3): 257–71PubMedCrossRef Wancata J, Windhaber J, Krautgartner M, et al. The consequences of non-cognitive symptoms of dementia in medical hospital departments. Int J Psychiatry Med 2003; 33(3): 257–71PubMedCrossRef
6.
go back to reference Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000 May; 157(5): 708–14PubMedCrossRef Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000 May; 157(5): 708–14PubMedCrossRef
7.
go back to reference Finkel SI. Behavioral and psychological symptoms of dementia: a current focus for clinicians, researchers, and caregivers. J Clin Psychiatry 2001; 62Suppl. 21: 3–6PubMed Finkel SI. Behavioral and psychological symptoms of dementia: a current focus for clinicians, researchers, and caregivers. J Clin Psychiatry 2001; 62Suppl. 21: 3–6PubMed
8.
go back to reference Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the Cardiovascular Health Study. JAMA 2002 Sep 25; 288(12): 1475–83PubMedCrossRef Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the Cardiovascular Health Study. JAMA 2002 Sep 25; 288(12): 1475–83PubMedCrossRef
9.
go back to reference Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer’s disease. Neurology 1996 Jan; 46(1): 130–5PubMedCrossRef Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer’s disease. Neurology 1996 Jan; 46(1): 130–5PubMedCrossRef
10.
go back to reference Sink KM, Covinsky KE, Newcomer R, et al. Ethnic differences in the prevalence and pattern of dementia-related behaviors. J Am Geriatr Soc 2004 Aug; 52(8): 1277–83PubMedCrossRef Sink KM, Covinsky KE, Newcomer R, et al. Ethnic differences in the prevalence and pattern of dementia-related behaviors. J Am Geriatr Soc 2004 Aug; 52(8): 1277–83PubMedCrossRef
11.
go back to reference Rosenberg PB, Onyike CU, Katz IR, et al. Clinical application of operationalized criteria for ‘Depression of Alzheimer’s Disease’. Int J Geriatr Psychiatry 2005 Feb; 20(2): 119–27PubMedCrossRef Rosenberg PB, Onyike CU, Katz IR, et al. Clinical application of operationalized criteria for ‘Depression of Alzheimer’s Disease’. Int J Geriatr Psychiatry 2005 Feb; 20(2): 119–27PubMedCrossRef
12.
go back to reference Tariot PN, Loy R, Ryan JM, et al. Mood stabilizers in Alzheimer’s disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev 2002 Dec 7; 54(12): 1567–77PubMedCrossRef Tariot PN, Loy R, Ryan JM, et al. Mood stabilizers in Alzheimer’s disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev 2002 Dec 7; 54(12): 1567–77PubMedCrossRef
13.
go back to reference Tariot PN, Raman R, Jakimovich L, et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer’s disease complicated by agitation: a randomized controlled trial. Am J Geriatr Psychiatry 2005 Nov; 13(11): 942–9PubMed Tariot PN, Raman R, Jakimovich L, et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer’s disease complicated by agitation: a randomized controlled trial. Am J Geriatr Psychiatry 2005 Nov; 13(11): 942–9PubMed
14.
go back to reference Tariot PN, Ismail MS. Use of quetiapine in elderly patients. J Clin Psychiatry 2002; 63Suppl. 13: 21–6PubMed Tariot PN, Ismail MS. Use of quetiapine in elderly patients. J Clin Psychiatry 2002; 63Suppl. 13: 21–6PubMed
15.
go back to reference Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999 Feb; 60(2): 107–15PubMedCrossRef Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999 Feb; 60(2): 107–15PubMedCrossRef
16.
go back to reference Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003 Feb; 64(2): 134–43PubMedCrossRef Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003 Feb; 64(2): 134–43PubMedCrossRef
17.
go back to reference De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999 Sep 22; 53(5): 946–55PubMedCrossRef De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999 Sep 22; 53(5): 946–55PubMedCrossRef
18.
go back to reference Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000 Oct; 57(10): 968–76PubMedCrossRef Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000 Oct; 57(10): 968–76PubMedCrossRef
19.
go back to reference Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006 Mar; 14(3): 191–210PubMed Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006 Mar; 14(3): 191–210PubMed
20.
go back to reference Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005 Feb 2; 293(5): 596–608PubMedCrossRef Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005 Feb 2; 293(5): 596–608PubMedCrossRef
21.
go back to reference Tariot PN. Treatment of agitation in dementia. J Clin Psychiatry 1999; 60Suppl. 8: 11–20PubMed Tariot PN. Treatment of agitation in dementia. J Clin Psychiatry 1999; 60Suppl. 8: 11–20PubMed
22.
go back to reference Meinhold JM, Blake LM, Mini LJ, et al. Effect of divalproex sodium on behavioural and cognitive problems in elderly dementia. Drugs Aging 2005; 22(7): 615–26PubMedCrossRef Meinhold JM, Blake LM, Mini LJ, et al. Effect of divalproex sodium on behavioural and cognitive problems in elderly dementia. Drugs Aging 2005; 22(7): 615–26PubMedCrossRef
23.
go back to reference Bains J, Birks JS, Dening TR. The efficacy of antidepressants in the treatment of depression in dementia. Cochrane Database Syst Rev 2002; (4): CD003944 Bains J, Birks JS, Dening TR. The efficacy of antidepressants in the treatment of depression in dementia. Cochrane Database Syst Rev 2002; (4): CD003944
24.
go back to reference Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998 Jan; 155(1): 54–61PubMed Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998 Jan; 155(1): 54–61PubMed
25.
go back to reference Tariot PN, Schneider LS, Mintzer JE. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial. Curr Ther Res 2001 Jan; 62(1): 51–67CrossRef Tariot PN, Schneider LS, Mintzer JE. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial. Curr Ther Res 2001 Jan; 62(1): 51–67CrossRef
26.
go back to reference Porsteinsson AP, Tariot PN, Erb R, et al. An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am J Geriatr Psychiatry 1997 Fall; 5(4): 344–51PubMedCrossRef Porsteinsson AP, Tariot PN, Erb R, et al. An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am J Geriatr Psychiatry 1997 Fall; 5(4): 344–51PubMedCrossRef
27.
go back to reference Porsteinsson AP, Tariot PN, Jakimovich LJ, et al. Valproate therapy for agitation in dementia: open-label extension of a double-blind trial. Am J Geriatr Psychiatry 2003 Jul–Aug; 11(4): 434–40PubMed Porsteinsson AP, Tariot PN, Jakimovich LJ, et al. Valproate therapy for agitation in dementia: open-label extension of a double-blind trial. Am J Geriatr Psychiatry 2003 Jul–Aug; 11(4): 434–40PubMed
28.
go back to reference Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001 Winter; 9(1): 58–66PubMed Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001 Winter; 9(1): 58–66PubMed
29.
go back to reference Mattson RH, Cramer JA. Valproate: interactions with other drugs. In: Levy R, Mattson R, Meldrum B, editors. Antiepileptic drugs. New York (NY): Raven, 1989: 621–32 Mattson RH, Cramer JA. Valproate: interactions with other drugs. In: Levy R, Mattson R, Meldrum B, editors. Antiepileptic drugs. New York (NY): Raven, 1989: 621–32
30.
go back to reference Mellow AM, Solano-Lopez C, Davis S. Sodium valproate in the treatment of behavioral disturbance in dementia. J Geriatr Psychiatry Neurol 1993 Oct–Dec; 6(4): 205–9PubMed Mellow AM, Solano-Lopez C, Davis S. Sodium valproate in the treatment of behavioral disturbance in dementia. J Geriatr Psychiatry Neurol 1993 Oct–Dec; 6(4): 205–9PubMed
31.
go back to reference Sival RC, Haffmans PM, van Gent PP, et al. The effects of sodium valproate on disturbed behavior in dementia. J Am Geriatr Soc 1994 Aug; 42(8): 906–7PubMed Sival RC, Haffmans PM, van Gent PP, et al. The effects of sodium valproate on disturbed behavior in dementia. J Am Geriatr Soc 1994 Aug; 42(8): 906–7PubMed
32.
go back to reference Home M, Lindley SE. Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes. J Clin Psychiatry 1995 Sep; 56(9): 430–1 Home M, Lindley SE. Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes. J Clin Psychiatry 1995 Sep; 56(9): 430–1
33.
go back to reference Lott AD, McElroy SL, Keys MA. Valproate in the treatment of behavioral agitation in elderly patients with dementia. J Neuropsychiatry Clin Neurosci 1995 Summer; 7(3): 314–9PubMed Lott AD, McElroy SL, Keys MA. Valproate in the treatment of behavioral agitation in elderly patients with dementia. J Neuropsychiatry Clin Neurosci 1995 Summer; 7(3): 314–9PubMed
34.
go back to reference Sandborn WD, Endfeldt F, Hamdy R. Valproic acid for physically aggressive behavior in geriatric patients with dementia. Am J Geriatr Psychiatry 1995; 3: 239–42CrossRef Sandborn WD, Endfeldt F, Hamdy R. Valproic acid for physically aggressive behavior in geriatric patients with dementia. Am J Geriatr Psychiatry 1995; 3: 239–42CrossRef
35.
go back to reference Puryear LJ, Kunik ME, Workman Jr R. Tolerability of divalproex sodium in elderly psychiatric patients with mixed diagnoses. J Geriatr Psychiatry Neurol 1995 Oct; 8(4): 234–7PubMed Puryear LJ, Kunik ME, Workman Jr R. Tolerability of divalproex sodium in elderly psychiatric patients with mixed diagnoses. J Geriatr Psychiatry Neurol 1995 Oct; 8(4): 234–7PubMed
36.
go back to reference Haas S, Vincent K, Holt J, et al. Divalproex: a possible treatment alternative for demented, elderly aggressive patients. Ann Clin Psychiatry 1997 Sep; 9(3): 145–7PubMed Haas S, Vincent K, Holt J, et al. Divalproex: a possible treatment alternative for demented, elderly aggressive patients. Ann Clin Psychiatry 1997 Sep; 9(3): 145–7PubMed
37.
go back to reference Kasckow JW, McElroy SL, Cameron RI. A pilot study on the use of divalproex sodium in the treatment of behavioral agitation in elderly patients with dementia: assessment with the BEHAVE-AD and CGI rating scales. Curr Ther Res 1997 Dec; 58(12): 981–9CrossRef Kasckow JW, McElroy SL, Cameron RI. A pilot study on the use of divalproex sodium in the treatment of behavioral agitation in elderly patients with dementia: assessment with the BEHAVE-AD and CGI rating scales. Curr Ther Res 1997 Dec; 58(12): 981–9CrossRef
38.
go back to reference Narayan M, Nelson JC. Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic. J Clin Psychiatry 1997 Aug; 58(8): 351–4PubMedCrossRef Narayan M, Nelson JC. Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic. J Clin Psychiatry 1997 Aug; 58(8): 351–4PubMedCrossRef
39.
go back to reference Herrmann N. Valproic acid treatment of agitation in dementia. Can J Psychiatry 1998 Feb; 43(1): 69–72PubMed Herrmann N. Valproic acid treatment of agitation in dementia. Can J Psychiatry 1998 Feb; 43(1): 69–72PubMed
40.
go back to reference Kunik ME, Puryear L, Orengo CA, et al. The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances. Int J Geriatr Psychiatry 1998 Jan; 13(1): 29–34PubMedCrossRef Kunik ME, Puryear L, Orengo CA, et al. The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances. Int J Geriatr Psychiatry 1998 Jan; 13(1): 29–34PubMedCrossRef
41.
go back to reference Gupta S, O’Connell RO, Parekh A. Efficacy of valproate for agitation and aggression in dementia: case reports. Int J Geriatr Psychopharmacol 1998; 1: 244–8 Gupta S, O’Connell RO, Parekh A. Efficacy of valproate for agitation and aggression in dementia: case reports. Int J Geriatr Psychopharmacol 1998; 1: 244–8
42.
go back to reference Goldberg RJ. The use of adjunctive divalproex for neuroleptic unresponsive behavioral disturbances in nursing home residents with dementia. Ann Long-Term Care 1999; 7: 63–6 Goldberg RJ. The use of adjunctive divalproex for neuroleptic unresponsive behavioral disturbances in nursing home residents with dementia. Ann Long-Term Care 1999; 7: 63–6
43.
go back to reference Takahashi M, Akagi M. [Case report of sodium valproate treatment of aggression associated with Alzheimer’s disease]. No To Shinkei 1996 Aug; 48(8): 757–60PubMed Takahashi M, Akagi M. [Case report of sodium valproate treatment of aggression associated with Alzheimer’s disease]. No To Shinkei 1996 Aug; 48(8): 757–60PubMed
44.
go back to reference Alexopoulos GS, Jeste DV, Chung H, et al. The expert consensus guideline series: treatment of dementia and its behavioral disturbances. Postgrad Med Special Report 2005 Jan: 1–111 Alexopoulos GS, Jeste DV, Chung H, et al. The expert consensus guideline series: treatment of dementia and its behavioral disturbances. Postgrad Med Special Report 2005 Jan: 1–111
45.
go back to reference Sival RC, Haffmans PM, Jansen PA, et al. Sodium valproate in the treatment of aggressive behavior in patients with dementia: a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry 2002; 17: 579–85PubMedCrossRef Sival RC, Haffmans PM, Jansen PA, et al. Sodium valproate in the treatment of aggressive behavior in patients with dementia: a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry 2002; 17: 579–85PubMedCrossRef
46.
go back to reference American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
47.
go back to reference McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS/ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984; 34: 939–44PubMedCrossRef McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS/ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984; 34: 939–44PubMedCrossRef
48.
go back to reference Patel V, Hope T. Aggressive behaviour in elderly people with dementia: a review. Int Geriatr Psychiatry 1993; 8: 457–72CrossRef Patel V, Hope T. Aggressive behaviour in elderly people with dementia: a review. Int Geriatr Psychiatry 1993; 8: 457–72CrossRef
49.
go back to reference Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 1999 May; 58(1): 31–59PubMedCrossRef Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 1999 May; 58(1): 31–59PubMedCrossRef
50.
go back to reference Gean PW, Huang CC, Hung CR, et al. Valproic acid suppresses the synaptic response mediated by the NMDA receptors in rat amygdalar slices. Brain Res Bull 1994; 33(3): 333–6PubMedCrossRef Gean PW, Huang CC, Hung CR, et al. Valproic acid suppresses the synaptic response mediated by the NMDA receptors in rat amygdalar slices. Brain Res Bull 1994; 33(3): 333–6PubMedCrossRef
51.
go back to reference Zeise ML, Kasparow S, Zieglgansberger W. Valproate suppresses N-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Res 1991 Mar 29; 544(2): 345–8PubMedCrossRef Zeise ML, Kasparow S, Zieglgansberger W. Valproate suppresses N-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Res 1991 Mar 29; 544(2): 345–8PubMedCrossRef
52.
go back to reference Ulas J, Cotman CW. Decreased expression of N-methyl-D-aspartate receptor 1 messenger RNA in select regions of Alzheimer brain. Neuroscience 1997 Aug; 79(4): 973–82PubMedCrossRef Ulas J, Cotman CW. Decreased expression of N-methyl-D-aspartate receptor 1 messenger RNA in select regions of Alzheimer brain. Neuroscience 1997 Aug; 79(4): 973–82PubMedCrossRef
53.
go back to reference Biggs CS, Pearce BR, Fowler LJ, et al. Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study. J Neurochem 1992 Nov; 59(5): 1702–8PubMedCrossRef Biggs CS, Pearce BR, Fowler LJ, et al. Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study. J Neurochem 1992 Nov; 59(5): 1702–8PubMedCrossRef
54.
go back to reference Chen G, Manji HK, Wright CB, et al. Effects of valproic acid on beta-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells. Neuropsychopharmacology 1996 Sep; 15(3): 271–80PubMedCrossRef Chen G, Manji HK, Wright CB, et al. Effects of valproic acid on beta-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells. Neuropsychopharmacology 1996 Sep; 15(3): 271–80PubMedCrossRef
55.
go back to reference Mark RJ, Ashford JW, Goodman Y, et al. Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology. Neurobiol Aging 1995 Mar–Apr; 16(2): 187–98PubMedCrossRef Mark RJ, Ashford JW, Goodman Y, et al. Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology. Neurobiol Aging 1995 Mar–Apr; 16(2): 187–98PubMedCrossRef
56.
go back to reference Chen G, Zeng WZ, Yuan PX, et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999 Feb; 72(2): 879–82PubMedCrossRef Chen G, Zeng WZ, Yuan PX, et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999 Feb; 72(2): 879–82PubMedCrossRef
57.
go back to reference Alexopoulos GS, Silver JM, Kahn DA, et al. The expert consensus guideline series: the treatment of agitation in older persons with dementia. Postgrad Med 1998; 103: 1–88 Alexopoulos GS, Silver JM, Kahn DA, et al. The expert consensus guideline series: the treatment of agitation in older persons with dementia. Postgrad Med 1998; 103: 1–88
58.
go back to reference Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. JAMA 1997 Oct 22–28; 278(16): 1363–71PubMedCrossRef Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. JAMA 1997 Oct 22–28; 278(16): 1363–71PubMedCrossRef
59.
go back to reference Lonergan ET, Cameron M, Luxenberg J. Valproic acid for agitation in dementia. Cochrane Database Syst Rev 2004; (2): CD003945 Lonergan ET, Cameron M, Luxenberg J. Valproic acid for agitation in dementia. Cochrane Database Syst Rev 2004; (2): CD003945
60.
go back to reference Depakote [package insert]. North Chicago (IL): Abbott Laboratories, 2004 Depakote [package insert]. North Chicago (IL): Abbott Laboratories, 2004
61.
go back to reference Trannel TJ, Ahmed I, Goebert D. Occurrence of thrombocytopenia in psychiatric patients taking valproate. Am J Psychiatry 2001 Jan; 158(1): 128–30PubMedCrossRef Trannel TJ, Ahmed I, Goebert D. Occurrence of thrombocytopenia in psychiatric patients taking valproate. Am J Psychiatry 2001 Jan; 158(1): 128–30PubMedCrossRef
62.
go back to reference Butler R. Strategies to delay dysfunction in later life. In: Dall JLC, Ermini M, Herrling P, et al., editors. Adaptations in aging. London: Academic Press, 1995: 289–97 Butler R. Strategies to delay dysfunction in later life. In: Dall JLC, Ermini M, Herrling P, et al., editors. Adaptations in aging. London: Academic Press, 1995: 289–97
63.
go back to reference Michel JP, Zekry D, Mulligan R, et al. Economic considerations of Alzheimer’s disease and related disorders. Aging (Milano) 2001 Jun; 13(3): 255–60 Michel JP, Zekry D, Mulligan R, et al. Economic considerations of Alzheimer’s disease and related disorders. Aging (Milano) 2001 Jun; 13(3): 255–60
Metadata
Title
Divalproex Sodium for the Treatment of Behavioural Problems Associated With Dementia in the Elderly
Author
Dr Anton P. Porsteinsson
Publication date
01-11-2006
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 11/2006
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200623110-00003

Other articles of this Issue 11/2006

Drugs & Aging 11/2006 Go to the issue

From the World Literature

Gerontology Forum

Review Article

HIV and Aging

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.